Biosyent (TSE:RX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioSyent Pharma Inc. has acquired the assets for Tibelia, a hormone replacement therapy drug, from Novalon SA and Mithra Pharmaceuticals SA, including intellectual property and global distribution rights, for up to EUR 2.8 million. This move is expected to bolster the company’s earnings by approximately 12% and aligns with BioSyent’s strategic goals of growth and diversification. Tibelia has been a key product in BioSyent’s women’s health portfolio since 2020, and with this acquisition, they can now supply it globally.
For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.